Off-Label Use Potential With J&J’s Xarelto Not A Factor In Review, FDA Says
Executive Summary
In reviewing the approvability of Johnson & Johnson's factor Xa inhibitorXarelto (rivaroxaban), FDA must remain focused on the proposed indication - despite the inclination to factor in the risks associated with potential off-label use, Office of Oncology Drug Products Director Richard Pazdur said
You may also be interested in...
J&J Xarelto Liver Profile Key To Committee Vote; New Data Offer Assurance
The FDA advisory committee review of Johnson & Johnson's anticoagulant rivaroxaban highlights a recurring regulatory issue for the agency and its expert panels: how to assess newly available data that is not included in the NDA, but could be key to a product's approvability
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?
US FDA Advisory Panels May Look Different Across Centers, Despite Efforts To Standardize Process
As FDA is readying to go back to in-person advisory committee meetings this fall, the centers have different ideas about how to use their expert panels.